AngioDynamics, Inc. has announced its financial results for the first quarter of fiscal year 2027, which ended on August 31, 2026. The report, issued on October 8, 2026, reveals a continued upward trajectory for the company, particularly in its medical technology segment. This growth is significant as it demonstrates AngioDynamics' ability to adapt and thrive in a competitive market.

AngioDynamics, based in Latham, New York, is a prominent player in the surgical and medical instruments and apparatus sector. The company is publicly traded on the Nasdaq under the ticker symbol ANGO. It is categorized under the SIC code 3841, which encompasses surgical and medical instruments and apparatus. Recent filings include a 10-Q and a DEFA14A, among others, all filed on October 8, 2026.

The latest filing highlights several key financial metrics. According to the report, AngioDynamics achieved net sales of $80.9 million for the quarter, marking a 6.9% increase compared to the same period last year. Notably, the Med Tech segment alone saw net sales of $39.9 million, reflecting a robust 13.2% year-over-year growth. In contrast, the Med Device segment reported $41.0 million in sales, with a more modest growth of 1.4%.

In addition to sales figures, the company reported a GAAP gross margin of 59.4% and a GAAP loss per share of $0.17. These results indicate that while the company is growing its top line, it is still facing challenges in achieving profitability. The filing also includes a press release and presentation slides that further detail AngioDynamics' financial performance and strategic direction.

The impact of these results may extend beyond AngioDynamics itself. Competitors in the surgical and medical instruments sector may need to reassess their strategies in light of AngioDynamics' continued growth and market presence. The company’s ability to deliver consistent growth in its Med Tech segment could signal to investors and industry players that there are ample opportunities for innovation and expansion in this field.

Looking ahead, the filing does not specify what actions AngioDynamics will take next. However, the company’s ongoing focus on enhancing its product offerings and improving patient care suggests that it will continue to pursue growth opportunities in the medical technology landscape.